Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2014 Jan;12(1):32-7.
doi: 10.1158/1541-7786.MCR-13-0341. Epub 2013 Oct 28.

FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs

Affiliations
Free article

FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs

Takehiko Yokobori et al. Mol Cancer Res. 2014 Jan.
Free article

Abstract (VSports手机版)

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. To improve the prognosis of patients with NSCLCs, new and validated therapeutic targets are critically needed. In this study, we focused on F-box and WD repeat domain containing-7 (FBXW7), an E3 ubiquitin ligase, that regulates the degradation of MCL1, Myc, cyclin E, and TOP2A VSports手机版. Importantly, loss of FBXW7 was associated with increased sensitivity of tumors to a class I-specific histone deacetylase (HDAC) inhibitor, MS-275. Immunohistochemical analysis revealed increased expression of FBXW7 targets, MCL1 and TOP2A, in NSCLC tumors with low expression of FBXW7. Moreover, clinical specimens exhibiting low FBXW7 expression presented with more progressive cancer and significantly shorter cancer-specific survival than patients with high FBXW7 expression. Mechanistic study of NSCLC cell lines with silenced FBXW7 revealed enhanced MS-275 sensitivity and taxol resistance. Interestingly, taxol resistance was eliminated by MS-275 treatment, suggesting the potential of HDAC inhibitors for the treatment of aggressive taxol-resistant NSCLCs that lack FBXW7. .

Implications: FBXW7 status impacts chemosensitivity and is a prognostic marker in NSCLCs. VISUAL OVERVIEW: http://mcr. aacrjournals. org/content/early/2013/12/19/1541-7786 V体育安卓版. MCR-13-0341/F1. large. jpg. .

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources